15 alternatives ranked by AI visibility score. Category: Microbiome Therapeutics.
Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clini
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapie
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nas
Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generativ
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeut